Marc Maliepaard
- Oncology top 1%
- Drug Transport and Resistance Mechanisms 10
- Metal complexes synthesis and properties 4
- Cancer Treatment and Pharmacology 4
-
- Pharmacological Effects and Toxicity Studies 5
- Toxicology top 2%
- Bioactive Compounds and Antitumor Agents 4
- Pharmacology top 2%
- Molecular Biology top 5%
- Cancer therapeutics and mechanisms 15
- DNA Repair Mechanisms 4
-
- Chemotherapy-induced organ toxicity mitigation 3
- Co-authors
- Jan H.M. SchellensGeorge L. SchefferIan F. FaneyteMarc J. van de VijverR J ScheperAlfred H. SchinkelDick PluimJ. Schellens
- Journals
- British Journal of Cancer (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)Anti-Cancer Drugs (2 papers)
- Partner nations
- NetherlandsUnited StatesGermany
In The Last Decade
Marc Maliepaard
32 papers receiving 2.9k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Oncology 2.2k
- Pediatrics, Perinatology and Child Health 730
- Toxicology 100
- Pharmacology 189
- Molecular Biology 1.3k
Countries citing papers authored by Marc Maliepaard
This map shows the geographic impact of Marc Maliepaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Maliepaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Maliepaard more than expected).
Fields of papers citing papers by Marc Maliepaard
This network shows the impact of papers produced by Marc Maliepaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Maliepaard. The network helps show where Marc Maliepaard may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Marc Maliepaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 0 | |
| 2 | 2013 | 4 | |
| 3 | 2003 | 11 | |
| 4 | Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. | 2003 | 7 |
| 5 | 2002 | 221 | |
| 6 | 2002 | 94 | |
| 7 | 2002 | 21 | |
| 8 | 2001 | 75 | |
| 9 | 2001 | 17 | |
| 10 | 2000 | 86 | |
| 11 | 1999 | 41 | |
| 12 | 1999 | 11 | |
| 13 | 1998 | 51 | |
| 14 | 1998 | 73 | |
| 15 | 1997 | 29 | |
| 16 | 1995 | 34 | |
| 17 | 1995 | 1 | |
| 18 | 1994 | 5 | |
| 19 | 1993 | 20 | |
| 20 | 1990 | 66 |
About Marc Maliepaard
Marc Maliepaard is a scholar working on Toxicology, Oncology and Pediatrics, Perinatology and Child Health, having authored 33 papers that have together received 2.9k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (15 papers), Drug Transport and Resistance Mechanisms (10 papers), Pharmacological Effects and Toxicity Studies (5 papers), Bioactive Compounds and Antitumor Agents (4 papers), DNA Repair Mechanisms (4 papers), Metal complexes synthesis and properties (4 papers), Cancer Treatment and Pharmacology (4 papers) and Chemotherapy-induced organ toxicity mitigation (3 papers). The work is most often cited by research in Oncology (2.2k citations), Pediatrics, Perinatology and Child Health (730 citations) and Toxicology (100 citations). Marc Maliepaard has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Jan H.M. Schellens, George L. Scheffer, Ian F. Faneyte, Marc J. van de Vijver, R J Scheper, Alfred H. Schinkel, Dick Pluim, J. Schellens, Rik J. Scheper and Jos H. Beijnen. Their work appears in journals such as British Journal of Cancer, Cancer Chemotherapy and Pharmacology, Anti-Cancer Drugs, Generics and Biosimilars Initiative Journal and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.